首页> 外文期刊>Canadian journal of anesthesia: Journal canadien d'anesthesie >Coagulation after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: a retrospective cohort analysis
【24h】

Coagulation after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: a retrospective cohort analysis

机译:细胞导致手术和高温腹膜内化疗后的凝血:回顾性队列队列分析

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Abstract Purpose Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) benefit patients with peritoneal carcinomatosis. Nevertheless, this therapy is associated with considerable postoperative pain due to the extensive abdominal incision. While epidural analgesia offers efficacious pain control, CRS and HIPEC therapy is associated with perioperative coagulopathy that may impact its use. The purpose of this retrospective study is to characterize the postoperative coagulopathy in this patient subset and to develop a model that will help predict those at risk. Methods Our database of patients treated with CRS and HIPEC ( n = 171) was reviewed to assess perioperative changes in platelet count, international normalized ratio (INR), and partial thromboplastin time (PTT). Abnormal coagulation was defined by platelet count ?9 ·L ?1 , INR ≥ 1.5, or PTT ≥ 45 sec. Severe abnormality in coagulation was defined by platelet count ?9 ·L ?1 , INR > 2.0, and/or PTT > 60 sec. A logistic regression model was developed to determine if patient, disease, and/or surgical factor(s) were associated with the development of postoperative coagulopathy. Epidural catheter management in this patient population was also reviewed. Results Significant differences (adjusted P ?9 ·L ?1 (POD 2 and POD 3), an increase in INR of 0.2 (POD 0 to POD 2), and a decrease in PTT of 3.1 sec (POD 5). Coagulopathy and severe coagulopathy occurred in 38% and 4.7% of patients, respectively. Predictors of coagulopathy included intraoperative transfusion of packed red blood cells (PRBCs) and perhaps the peritoneal carcinomatosis index (PCI). Epidural catheters were inserted in 26 patients for a median [IQR] duration of 7.0 [5.0-7.0] days without complication. At the time of their removal, no blood products were required to correct abnormal coagulation values. Conclusions Altered coagulation may appear during the postoperative period in approximately 40% of our patients treated with CRS and HIPEC. Intraoperative transfusion of RBCs and possibly increased PCI are associated with abnormal postoperative coagulation. Close monitoring of coagulation parameters is required to help ensure safe removal of an epidural catheter.
机译:摘要目的细胞功能性手术(CRS)和高温腹膜内化疗(高温)患有腹膜癌症的患者。然而,由于腹部广泛的腹部切口,这种治疗与显着的术后疼痛有关。虽然硬膜外镇痛提供有效的疼痛控制,但CRS和Hipec治疗与可能影响其使用的围手术期凝结病有关。该回顾性研究的目的是在该患者子集中表征术后凝结病,并开发一个有助于预测风险的模型。方法对CRS和HIPEC(N = 171)治疗的患者数据库进行审查,评估血小板计数,国际归一化比(INR)和部分血栓形成时间(PTT)的围手术期变化。异常凝血由血小板计数Δ9·1?1,INR≥1.5,或PTT≥45秒。凝血中的严重异常由血小板计数α9·9·1,INR> 2.0和/或PTT> 60秒定义。开发了一种物流回归模型以确定患者,疾病和/或外科因素是否与术后凝血病的发展有关。还审查了这种患者人口的硬膜外导管管理。得到显着的差异(调节的P?9·L?1(POD 2和POD 3),0.2的INR增加(POD 0到POD 2),以及PTT的降低为3.1秒(吊舱5)。凝结病变和严重凝血病分别发生在38%和4.7%的患者。凝血病的预测因子包括腹腔内输血(PRBC),也许是腹膜癌症指数(PCI)。在26名患者中插入硬膜外导管,以进行中位数[IQR]持续时间为7.0 [5.0-7.0]天没有并发症。在移除时,不需要血液产物来纠正异常凝固值。结论在术后期间可能会出现在术后,在我们的约40%患者治疗CRS和Hipec。RBCs的术中输血和可能增加的PCI与异常术后凝固有关。需要密切监测凝血参数,以帮助确保安全移除硬膜外导管。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号